Clinical Trial

DPTX3186 in Wnt Pathway Activated Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07312903
Lead Sponsor Dewpoint Therapeutics
Conditions Solid Tumors
Enrollment 40 participants
Start Date 2026-01
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-12